N4 Pharma PLC Holding(s) in Company (9131U)
17 July 2018 - 10:12PM
UK Regulatory
TIDMN4P
RNS Number : 9131U
N4 Pharma PLC
17 July 2018
N4 Pharma Plc
("N4 Pharma" or the "Company")
Holdings in Company
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
which reformulates existing drugs and vaccines to improve their
performance, announces that it was notified on 16 July 2018 that Mr
David Farrier, an existing Substantial Shareholder in the Company
(as defined in the AIM Rules for Companies), is beneficially
interested in 11,675,366 ordinary shares of 0.4 pence each,
representing 12.8 per cent. of the Company's issued share
capital.
Enquiries:
N4 Pharma Plc
Nigel Theobald, CEO Via Alma PR
Stockdale Securities Tel: +44(0)207 601 6100
Tom Griffiths / David
Coaten
Alma PR
Josh Royston Tel: +44(0)778 090 1979
Robyn Fisher Tel: +44(0)754 070 6191
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company which
reformulates existing drugs and vaccines to improve their
performance.
N4 Pharma's reformulation work falls under two divisions:
-- generic, already commercialised, drugs; and
-- novel delivery system for nucleic acids.
N4 Pharma has identified a number of established drugs that
could be improved upon through its reformulation techniques. N4
Pharma's most advanced reformulation is for sildenafil, widely
marketed as Viagra, where N4 Pharma is seeking to improve the speed
at which the drug takes effect whilst also extending its duration
of action.
N4 Pharma's reformulation approach should take approximately
three years to obtain regulatory approval as opposed to the
traditional process for new drugs of on average ten years. The cost
and risk profile of this model is also significantly less than the
traditional process. N4 Pharma's business model for generics is to
take reformulated drugs from its portfolio through to the stage
where it will license its newly reformulated drugs to
pharmaceutical companies to commercialise them. N4 Pharma's
revenues should be derived from up front milestone and royalty
payments associated with the licence.
N4 Pharma's business model for Nuvec(R) nanoparticles is to
undertake the required pre-clinical work to demonstrate the
capability of its nucleic acid delivery system as part of a vaccine
and/or method to deliver DNA/RNA so that it can license the
technology to major players developing treatments in this area,
again in return for up front milestone and royalty payments
associated with the licence.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
HOLLLFLFDIIDLIT
(END) Dow Jones Newswires
July 17, 2018 08:12 ET (12:12 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
From Apr 2024 to May 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
From May 2023 to May 2024